Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
50.89  0.14 (0.28%) 03-01 16:00
Open: 50.94 Pre. Close: 50.75
High: 51.07 Low: 50.445
Volume: 10,889,986 Market Cap: 102,909(M)
Stock Technical Analysis
Target: Six months: 60.64
One year: 70.83
Support: Support1: 49.24
Support2: 47.58
Resistance: Resistance1: 51.92
Resistance2: 60.64
Pivot: 50.25
Moving Averages: MA(5): 50.72
MA(20): 49.86
MA(100): 51.29
MA(250): 59.12
MACD: MACD(12,26): 0.28
Signal(12,26,9): 0.11
%K %D: %K(14,3): 71.71
%D(3): 70.65
RSI: RSI(14): 56.07
52-Week: High: 71.07
Low: 47.58
Change(%): -26.6
Average Vol(K): 3-Month: 15109
10-Days: 10776
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 51.124 - 51.485 51.485 - 51.764
Low: 49.759 - 50.145 50.145 - 50.445
Close: 50.39 - 50.983 50.983 - 51.443
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ BMY ] has closed below upper band by 31.0%. Bollinger Bands are 11.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Stock chart
Stock News
Fri, 01 Mar 2024
Bristol Myers Squibb Co. stock rises Friday, still underperforms market - MarketWatch

Fri, 01 Mar 2024
Bristol Myers Squibb Announces Dividend - Yahoo Finance

Fri, 01 Mar 2024
Bristol Myers Squibb Announces Dividend | Wire | - Chronicle-Tribune

Fri, 01 Mar 2024
Why Bristol-Myers Squibb Is A Buy? Acquirer's Multiple Stock Screener Analysis - The Acquirer's Multiple

Fri, 01 Mar 2024
Bristol-Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at - AmericanBankingNEWS

Thu, 29 Feb 2024
April 12th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 2020.00
Shares Float (M) 2020.00
% Held by Insiders 0.09
% Held by Institutions 79.13
Shares Short (K) 31090
Shares Short Prior Month (K) 22310
Stock Financials
EPS 3.860
Book Value (p.s.) 14.560
Profit Margin 17.83
Operating Margin 17.01
Return on Assets (ttm) 5.6
Return on Equity (ttm) 26.5
Qtrly Rev. Growth 0.6
Gross Profit (p.s.)
Sales Per Share 22.282
EBITDA (p.s.) 9.119
Qtrly Earnings Growth -8.90
Operating Cash Flow (M) 13860.00
Levered Free Cash Flow (M) 13780.00
Stock Valuation
PE Ratio 13.18
PEG Ratio -2.58
Price to Book value 3.50
Price to Sales 2.28
Price to Cash Flow 7.42
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android